Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

SP-102

Other · developed by Scilex Pharmaceuticals

Phase 3 Most advanced trial (none active)
SCLX Developer
1 Registered trials

What is SP-102?

SP-102 is an investigational drug studied in Lumbosacral Radicular Pain.

At a glance

Drug type
Other
Therapy area
Neurology
Developer
Scilex Pharmaceuticals, Inc. (SCLX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03372161 Phase 3 Lumbosacral Radicular Pain Completed SCLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lumbosacral Radicular Pain

More from Scilex Pharmaceuticals

SP-103 Phase 2

Follow SCLX, the company behind SP-102

See SCLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SCLX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.